Project SIRT6 Activator
ConditionAging
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age50-80
SponsorNational University of Singapore
About this trial
The global ageing population is increasingly affected by age-related diseases, which are challenging healthcare systems. Current treatments often extend lifespan without improving healthspan. The geroscience hypothesis suggests that targeting the ageing process could prevent or delay multiple diseases, enhancing healthspan. Fucoidan, a sulfated polysaccharide from brown macroalgae, is a safe dietary supplement with Sirtuin-6 (SIRT6) activating properties, which are linked to longevity. Clinical studies have shown that it reduces inflammatory markers associated with biological aging and frailty and influences DNA methylation in vitro and in vivo; however, its effects on human DNA methylation remain unknown.
Eligibility criteria
Qualifiers
50-80 years males;
Resident of Singapore (citizenship or permanent residency is not required);
Prefrail according to Fried frailty phenotype score;
English-literate who can understand, read and write in English;
Disqualifiers
Pre-existing or history of major cardiovascular disease (e.g., coronary artery disease, heart failure, stroke, peripheral vascular disease);
Current cancer or non-stable chronic obstructive pulmonary disease (COPD);
Use of anticoagulant medication;
Consuming seaweed more than 3 times a week;
Trial design
Treatments tested in this trial
- Fucoidan
- Placebo
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
National University of Singapore
Lead sponsor
University of Rochester
Collaborator
L'Oreal
Collaborator
DoNotAge.org
Collaborator
Source ClinicalTrials.gov